Place of centrally acting muscle relaxants in the treatment of non-specific back pain
The paper considers modern strategies for pharmacological treatment of non-specific back pain. It has been shown that despite some controversial approaches to the treatment according to the latest clinical guidelines, central muscle relaxants still play an important role in the treatment of back pain is significantly increased. At the same time, non-narcotic analgesics (paracetamol) are no longer considered as first line drugs for the treatment of acute back pain, as recommended several years ago. The analysis was carried out of the group of centrally acting muscle relaxants. Significant heterogeneity of the group and individual differences between various drugs are shown. As for some preparations of the group, their manufacturers received instructions from the regulatory authorities due to the unfavorable benefit/risk ratio. Cyclobenzaprine, one of the central muscle relaxants, which is new on the pharmaceutical market of Ukraine, is considered with more details. It is noted that one of major advantages is the dosage form of this drug with a slow release of the active substance. This allows cyclobenzaprine to be used once a day and contributes to improving the safety profile and patient’s compliance.
Full Text:PDF (Українська)
Andersson G.B. Epidemiological features of chronic low-back pain // Lancet. — 1999. — 354. — Р. 581-5.
Birklein F. Mechanism-based treatment principles of neuropathic pain // Fortschr. Neurol. Psychiatr. — 2002. — 70(2). — Р. 88-94.
Borenstein D.G., Calin A. Fast facts: Low Back Pain. — Health Press Limited, 2012. — 143 p.
Browning R., Jackson J.L., O’Malley P.G. Cyclobenzaprine and back pain: a meta‑analysis // Arch. Intern. Med. — 2001. — 161(13). — Р. 1613-1620.
Darwish M., Hellriegel E.T., Xie F. Single‑dose pharmacokinetics of once‑daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults: a randomized, open‑label, two‑period crossover, single‑centre study // Clin. Drug Investig. — 2008. — 28(12). —
Deyo R.A., Mirza S.K., Martin B.I. Back pain prevalence and visit rates: estimates from US national surveys, 2002 // Spine. — 2006. — 31. — Р. 2724-7.
Hucker H.B., Stauffer S.C., Balletto A.J., White S.D., Zacchei A.G., Arison B.H. Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man // Drug Metab. Dispos. — 1978. — 6(6). — Р. 659-672.
Katz J.N. Lumbar disk disorders and low — back pain: socioeconomic factors and consequences // J. Bone Joint Surg. Am. — 2006. — 88, Suppl. 2. — Р. 21-4.
Low back pain and sciatica in over 16s: assessment and ma-nagement. NICE guideline. Published: 30 November 2016 // http://nice.org.uk
Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Published 4 April 2017 // http://an-nals.org/aim/
Press release, EMA, 21 June 2012 // http://www.ema.europa.eu
Press release, EMA, 22 November 2013 // http://www.ema.europa.eu
Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Published 4 April 2017 // http://an-
Weil A.J. et al. Efficacy and tolerability of cyclobenzaprine extended release for acute muscle spasm: a pooled analysis // Postgrad. Med. — 2010 Jul. — 122(4). — Р. 158-69. doi: 10.3810/pgm.2010.07.2182.
Copyright (c) 2018 INTERNATIONAL NEUROLOGICAL JOURNAL
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2018